A PHP Error was encountered
Severity: Warning
Message: fopen(/var/lib/php/sessions/ci_sessionr6c9praj8l5mvkojhg18174clcu1ov20): Failed to open stream: No space left on device
Filename: drivers/Session_files_driver.php
Line Number: 177
Backtrace:
File: /var/www/html/index.php
Line: 316
Function: require_once
A PHP Error was encountered
Severity: Warning
Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)
Filename: Session/Session.php
Line Number: 137
Backtrace:
File: /var/www/html/index.php
Line: 316
Function: require_once
The impact of venous thrombosis on quality of life.
Thromb Res
Unit of Psychology, Leiden University Medical Center, P.O. Box 9555, 2300 RB Leiden, The Netherlands.
Published: January 2005
Quality of life (QOL) is increasingly seen as an important outcome in clinical care. Etiology, diagnosis, and management of venous thrombosis have been studied extensively, but only few studies have examined the impact of venous thrombosis on quality of life. The purpose of this study was to examine the impact of venous thrombosis on quality of life in a well-defined population of patients with venous thrombosis, by using both a generic and a disease-specific quality of life measure. A total of 45 patients from the thrombosis clinic of the University of Vermont in Burlington, VT, returned a mailed questionnaire including the Short-Form 36 (SF-36) and a disease-specific venous thrombosis-quality of life (VT-QOL) questionnaire about the problems faced by patients with venous thrombosis. The sample consisted of 13 men (28.9%) and 32 women (71.1%). The mean age was 44.1 years, with a range from 21 to 80 years. Compared with population norms of a general U.S. population that were adjusted for age and sex (N= 2463), venous thrombosis patients scored significantly lower (p < 0.05) on all subscales of the SF-36. Patients with the postthrombotic syndrome (PTS) appeared to have more impairment in their quality of life as measured by both the SF-36 and the disease-specific questionnaire. All correlations between the SF-36 subscales and the subscales of the VT-QOL were significant, most of them on a p < 0.01 level. Given the impact of venous thrombosis and the postthrombotic syndrome on quality of life, assessment of QOL should be included in future studies on the outcome of venous thrombosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.thromres.2004.04.007 | DOI Listing |
Similar Publications
Single-center retrospective study on the clinical application of multi-arm robotic-assisted uniportal video-assisted thoracic surgery.
J Robot Surg
March 2025
Department of Thoracic Surgery II, Xinjiang Medical University Affiliated Tumor Hospital, Urumqi, 830011, Xinjiang, China.
This research aims to consolidate clinical experiences with hybrid multi-arm robotic-assisted uniportal thoracoscopic surgery (H-URATS) employing endoscopic staplers and assess its safety and feasibility. A retrospective review was conducted on the clinical records of 128 patients treated with H-URATS at the Department of Thoracic Surgery II, Xinjiang Medical University Affiliated Tumor Hospital, between January and December 2024. The cohort included 52 men and 76 women, with an average age of 57.
View Article and Find Full Text PDFHereditary antithrombin deficiency and venous thrombosis in pregnancy - results of a retrospective multicenter study.
J Thromb Haemost
March 2025
Department of Haematology, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Background: The optimal anticoagulant regimen to prevent pregnancy-related venous thrombosis (VT) in women with antithrombin (AT) deficiency is unknown.
Objectives: To identify optimal doses of low molecular weight heparin (LMWH) to prevent pregnancy-related VT, and to investigate if AT concentrate peripartum could reduce postpartum VT in women with AT deficiency.
Methods: This retrospective study includes 115 pregnancies in 57 women with subclassified AT deficiency treated with LMWH in Denmark, Norway and Sweden (1991-2017).
Clinical Outcomes of Extended Venous Thromboembolism Prophylaxis, After Oncologic Colorectal Surgery.
J Gastrointest Surg
March 2025
Department of Surgery, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA, 72205; Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Translational Research Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA, 72205; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address:
Introduction: Current guidelines recommend extended venous thromboembolism (VTE) prophylaxis after colorectal surgery for cancer, but adherence to these guidelines has been low. Moreover, its effectiveness has not been evaluated using real-world data.
Methods: We retrospectively analyzed a random 25% sample of the 2009-2022 IQVIA Pharmetrics® Plus for Academics (IPPA) database, an administrative claims database representative of the commercially insured population of the United States.
Who are we bridging? Description of warfarin patients receiving injectable bridging therapy.
Thromb Res
March 2025
University of Utah College of Pharmacy, Department of Pharmacotherapy, 30 South 2000 East, Salt Lake City, UT 84112, USA; University of Utah Health Thrombosis Service, 6056 Fashion Square Drive, Suite 2420, Murray, UT 84107, USA.
Purpose: The evidence guiding the decision to provide injectable anticoagulant bridging therapy during periods of subtherapeutic warfarin anticoagulation is sparse. This study aims to identify the types of patients currently bridged within an academic medical center's Thrombosis Service, to highlight patient populations for future study of bridging outcomes.
Methods: This descriptive cohort study included patients taking warfarin managed by University of Utah Health Thrombosis Service who received outpatient enoxaparin bridging between January 1 and December 31, 2022.
Addressing the Pathophysiology of Venous Thrombosis and Chronic Kidney Disease in Sickle Cell Trait Using a Mouse Model.
Blood Adv
March 2025
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States.
Sickle cell trait (SCT) is present in subjects who possess a single copy of the bS-globin gene mutation. While most affected individuals are asymptomatic, SCT is a well-established risk factor for venous thrombosis and renal complications, including chronic and end-stage kidney disease. Following prolonged hypoxia, SCT red blood cells (RBCs) can undergo sickling, and hypoxia-mediated RBC sickling can be enhanced by cellular dehydration, hyperosmolarity and/or acidosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.